Human Metapneumovirus (hMPV) Therapeutics Global Market Report 2025

Description

Human metapneumovirus (hMPV) therapeutics refers to medical treatments aimed at managing and alleviating the symptoms caused by hMPV, a respiratory virus that typically affects infants, older adults, and immunocompromised individuals. These therapeutics work by inhibiting viral replication, blocking the virus from entering host cells, and modulating the immune response to reduce inflammation and the severity of the disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug classes for hMPV therapeutics include antipyretics, decongestants, cough suppressants, and other related medications. An antipyretic is a substance that helps reduce fever by lowering the body's temperature, acting on the hypothalamus. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They are utilized in various end-use settings such as hospitals, clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

The human metapneumovirus (hMPV) therapeutics market research report is one of a series of new reports from The Business Research Company that provides human metapneumovirus (hMPV) therapeutics market statistics, including the human metapneumovirus (hMPV) therapeutics industry global market size, regional shares, competitors with the human metapneumovirus (hMPV) therapeutics market share, detailed human metapneumovirus (hMPV) therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the human metapneumovirus (hMPV) therapeutics industry. This human metapneumovirus (hMPV) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human metapneumovirus (hMPV) therapeutics market size has grown strongly in recent years. It will grow from $0.66 billion in 2024 to $0.70 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to increased awareness of viral respiratory infections, a rising incidence of pediatric respiratory illnesses, higher hospitalization rates, expanded global health surveillance efforts, and a growing research focus on emerging respiratory viruses.

The human metapneumovirus (hMPV) therapeutics market size is expected to see strong growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected during the forecast period can be attributed to the rising demand for supportive care treatments, increased government and NGO funding, growing awareness of respiratory infections, a rise in pediatric respiratory illness cases, and a higher demand for targeted therapies. Key trends during this period include the integration of technology in diagnostic platforms, advancements in antiviral drug development, progress in vaccine research and delivery systems, technology-driven point-of-care testing, and improvements in molecular diagnostics.

The growing prevalence of respiratory infections is expected to significantly drive the expansion of the human metapneumovirus (hMPV) therapeutics market in the future. Respiratory infections affect the respiratory tract, which includes the nose, throat, airways, and lungs. The increasing number of these infections is largely attributed to rising levels of air pollution. Pollutants such as particulate matter and nitrogen dioxide can irritate and weaken the respiratory tract, making individuals more vulnerable to infections. hMPV therapeutics play a crucial role in treating respiratory infections caused by hMPV by reducing viral replication and inflammation through antiviral treatments and supportive care. This improves health outcomes, especially for vulnerable groups such as infants, the elderly, and immunocompromised patients. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that Chronic Obstructive Pulmonary Disease (COPD) contributed to 3.6% of Australia's total disease burden in 2023. COPD accounted for 50% of the overall respiratory disease burden, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Therefore, the increasing prevalence of respiratory infections is driving growth in the human metapneumovirus (hMPV) therapeutics market.

Leading companies in the human metapneumovirus (hMPV) therapeutics market are focusing on developing targeted antiviral therapies, such as monoclonal antibodies, to effectively treat hMPV infections. Monoclonal antibodies (mAbs) are laboratory-produced proteins that replicate the immune system's natural ability to fight diseases. These antibodies offer targeted therapy for a range of conditions, including cancer and autoimmune disorders, by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a UK-based biopharmaceutical company, secured $100 million in Series B financing, led by TCGX with support from Goldman Sachs Alternatives and other investors. This funding will advance the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting RSV and hMPV, with preliminary results expected by mid-2025. The funding will also accelerate the development of VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, aiming to address significant medical challenges in older populations.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical giant, acquired Icosavax, Inc. for $1.1 billion. This acquisition allows AstraZeneca to strengthen its vaccine and respiratory infection portfolio by incorporating Icosavax's innovative virus-like particle (VLP) technology and its potential first-in-class combination vaccine for RSV and hMPV. Icosavax, Inc., a U.S.-based biopharmaceutical company, is developing virus-like particle vaccines, including a promising first-in-class combination vaccine targeting both RSV and hMPV.

Major players in the human metapneumovirus (hmpv) therapeutics market are Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Riverside Health System, Narayana Health, Vir Biotechnology Inc., Fortis Healthcare, Apollo Diagnostics, Pathkind Diagnostics Pvt Ltd, Max Healthcare, LalPathLabs, Bio Farma, Metropolis Healthcare, American Lung Association, Enanta Pharmaceuticals Inc., Regency Healthcare, The Native Antigen Company, Max Lab, Agilus Diagnostics.

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus (hMPV) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human metapneumovirus (hMPV) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human metapneumovirus (hMPV) therapeutics market consists of revenues earned by entities providing services such as antiviral drug development, vaccine research, diagnostic testing, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus (hMPV) therapeutics market also includes sales of antiviral medications, immunotherapies, vaccines, and related diagnostic kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Metapneumovirus (hMPV) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human metapneumovirus (hmpv) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human metapneumovirus (hmpv) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human metapneumovirus (hmpv) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Antipyretic; Decongestants; Cough Suppressants; Other Drug Class
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-Use: Hospitals And Clinics; Diagnostic And Reference Laboratories; Academic And Research Institutions; Other End-Uses
Subsegments:
1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)
2) By Decongestants: Nasal Decongestants, Oral Decongestants
3) By Cough Suppressants: Dextromethorphan, Codeine, Benzonatate
4) By Other Drug Class: Antiviral Agents, Antibiotics (if secondary bacterial infection occurs), Inhaled Corticosteroids
Companies Mentioned: Sanofi S.A; AstraZeneca Plc; Merck KGaA; Moderna Inc; Riverside Health System
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34872

1. Executive Summary

2. Human Metapneumovirus (hMPV) Therapeutics Market Characteristics

3. Human Metapneumovirus (hMPV) Therapeutics Market Trends And Strategies

4. Human Metapneumovirus (hMPV) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Metapneumovirus (hMPV) Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Human Metapneumovirus (hMPV) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Metapneumovirus (hMPV) Therapeutics Market Growth Rate Analysis
5.4. Global Human Metapneumovirus (hMPV) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Metapneumovirus (hMPV) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Metapneumovirus (hMPV) Therapeutics Total Addressable Market (TAM)

6. Human Metapneumovirus (hMPV) Therapeutics Market Segmentation

6.1. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antipyretic
Decongestants
Cough Suppressants
Other Drug Class
6.2. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.3. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Diagnostic And Reference Laboratories
Academic And Research Institutions
Other End-Uses
6.4. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Antipyretic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Acetaminophen (Paracetamol)
6.5. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Decongestants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nasal Decongestants
Oral Decongestants
6.6. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Cough Suppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dextromethorphan
Codeine
Benzonatate
6.7. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiviral Agents
Antibiotics
Inhaled Corticosteroids

7. Human Metapneumovirus (hMPV) Therapeutics Market Regional And Country Analysis

7.1. Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market

8.1. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Metapneumovirus (hMPV) Therapeutics Market

9.1. China Human Metapneumovirus (hMPV) Therapeutics Market Overview
9.2. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Metapneumovirus (hMPV) Therapeutics Market

10.1. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Metapneumovirus (hMPV) Therapeutics Market

11.1. Japan Human Metapneumovirus (hMPV) Therapeutics Market Overview
11.2. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Metapneumovirus (hMPV) Therapeutics Market

12.1. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market

13.1. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Metapneumovirus (hMPV) Therapeutics Market

14.1. South Korea Human Metapneumovirus (hMPV) Therapeutics Market Overview
14.2. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market

15.1. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market Overview
15.2. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Metapneumovirus (hMPV) Therapeutics Market

16.1. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Metapneumovirus (hMPV) Therapeutics Market

17.1. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Metapneumovirus (hMPV) Therapeutics Market

18.1. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Metapneumovirus (hMPV) Therapeutics Market

19.1. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Metapneumovirus (hMPV) Therapeutics Market

20.1. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market

21.1. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market Overview
21.2. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Metapneumovirus (hMPV) Therapeutics Market

22.1. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Metapneumovirus (hMPV) Therapeutics Market

23.1. North America Human Metapneumovirus (hMPV) Therapeutics Market Overview
23.2. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Metapneumovirus (hMPV) Therapeutics Market

24.1. USA Human Metapneumovirus (hMPV) Therapeutics Market Overview
24.2. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Metapneumovirus (hMPV) Therapeutics Market

25.1. Canada Human Metapneumovirus (hMPV) Therapeutics Market Overview
25.2. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Metapneumovirus (hMPV) Therapeutics Market

26.1. South America Human Metapneumovirus (hMPV) Therapeutics Market Overview
26.2. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Metapneumovirus (hMPV) Therapeutics Market

27.1. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Metapneumovirus (hMPV) Therapeutics Market

28.1. Middle East Human Metapneumovirus (hMPV) Therapeutics Market Overview
28.2. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Metapneumovirus (hMPV) Therapeutics Market

29.1. Africa Human Metapneumovirus (hMPV) Therapeutics Market Overview
29.2. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape And Company Profiles

30.1. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape
30.2. Human Metapneumovirus (hMPV) Therapeutics Market Company Profiles
- 30.2.1. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Moderna Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Riverside Health System Overview, Products and Services, Strategy and Financial Analysis

31. Human Metapneumovirus (hMPV) Therapeutics Market Other Major And Innovative Companies

31.1. Narayana Health
31.2. Vir Biotechnology Inc.
31.3. Fortis Healthcare
31.4. Apollo Diagnostics
31.5. Pathkind Diagnostics Pvt Ltd
31.6. Max Healthcare
31.7. LalPathLabs
31.8. Bio Farma
31.9. Metropolis Healthcare
31.10. American Lung Association
31.11. Enanta Pharmaceuticals Inc.
31.12. Regency Healthcare
31.13. The Native Antigen Company
31.14. Max Lab
31.15. Agilus Diagnostics

32. Global Human Metapneumovirus (hMPV) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Metapneumovirus (hMPV) Therapeutics Market

34. Recent Developments In The Human Metapneumovirus (hMPV) Therapeutics Market

35. Human Metapneumovirus (hMPV) Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Human Metapneumovirus (hMPV) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Metapneumovirus (hMPV) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Metapneumovirus (hMPV) Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34872_Human_Metapneumovirus_hMPV_Therapeutics_GMR_2025